Další formáty:
BibTeX
LaTeX
RIS
@article{1834417,
author = {Vicha, Marek and Skala, Tomas and Jelinek, Libor and Pavlu, Ludek and Jarkovský, Jiří and Dušek, Ladislav and Benešová, Klára and Taborsky, Milos},
article_location = {Olomouc},
article_number = {2},
doi = {http://dx.doi.org/10.5507/bp.2021.069},
keywords = {diabetes mellitus; heart failure; pharmacotherapy; National Register of Paid Health Services (NRHZS)},
language = {eng},
issn = {1213-8118},
journal = {Biomedical Papers, Olomouc: Palacky University},
title = {Pharmacotherapy of diabetes mellitus in patients with heart failure-a nation-wide analysis of contemporary treatment},
url = {https://biomed.papers.upol.cz/corproof.php?tartkey=bio-000000-3089},
volume = {167},
year = {2023}
}
TY - JOUR
ID - 1834417
AU - Vicha, Marek - Skala, Tomas - Jelinek, Libor - Pavlu, Ludek - Jarkovský, Jiří - Dušek, Ladislav - Benešová, Klára - Taborsky, Milos
PY - 2023
TI - Pharmacotherapy of diabetes mellitus in patients with heart failure-a nation-wide analysis of contemporary treatment
JF - Biomedical Papers, Olomouc: Palacky University
VL - 167
IS - 2
SP - 177-184
EP - 177-184
PB - Palacky University
SN - 12138118
KW - diabetes mellitus
KW - heart failure
KW - pharmacotherapy
KW - National Register of Paid Health Services (NRHZS)
UR - https://biomed.papers.upol.cz/corproof.php?tartkey=bio-000000-3089
N2 - Aim. Retrospective national sub-analysis of antidiabetic pharmacotherapy in patients with diabetes mellitus (DM) and heart failure (HF) based on data reported to the National Register of Paid Health Services in the Czech Republic between 2012-2018. Methodology and Results. In 2012, there were 75,022 patients with HF and DM (i.e. 42.5% of patients with HF), 6 years later 117,265 (i.e. 41.0% of HF patients in 2018). The most represented antidiabetic drug was metformin (45.6%). Of the insulins and analogues, glargine showed the largest positive trend (5.8% 2012; 14.8% 2018). Empagliflozin was the most prescribed SGLT-2 inhibitor (1.8% in 2018). A decrease in prescribing was observed for saxagliptin (0.5% 2012; 0.1% 2018) and for sulfonylurea derivates - gliclazide (13.0% 2012; 10.3% in 2018) and glimepiride (12.9% 2012; 9.0% 2018). Linagliptin was the most prescribed dipeptidyl peptidase inhibitor (0.7% 2012; 6.8% 2018). Conclusion. In the Czech Republic, between 2012 and 2008, there was an increase in prevalence of patients with heart failure and concomitant diabetes mellitus, their proportion being similar. In correspondence with other registries, metformin was used mostly. A positive trend was observed in prescription of DDP-4 and SGLT-2 inhibitors, while there was a significant decrease in patients taking sulfonylureas.
ER -
VICHA, Marek, Tomas SKALA, Libor JELINEK, Ludek PAVLU, Jiří JARKOVSKÝ, Ladislav DUŠEK, Klára BENEŠOVÁ a Milos TABORSKY. Pharmacotherapy of diabetes mellitus in patients with heart failure-a nation-wide analysis of contemporary treatment. \textit{Biomedical Papers, Olomouc: Palacky University}. Olomouc: Palacky University, 2023, roč.~167, č.~2, s.~177-184. ISSN~1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2021.069.
|
